Addition of immunotherapy to chemotherapy improves progression-free survival in anal canal
The PODIUM-303 study shows practice-changing results for patients with unresectable locally recurrent or metastatic squamous cell carcinoma of the anal canal
Doublet immunotherapy consolidates its role in hepatocellular carcinoma
Benefits reported for the combination of ipilimumab and nivolumab further expand alternative therapeutic options for patients with unresected advanced disease
Ten years of improvement in the treatment of liver cancer
Novel agents, a rethinking of accepted treatment concepts and new roles for older treatment modalities are now driving liver cancer management
Blood-based tests show promise in improving hepatocellular carcinoma management
Innovative approaches are investigated to predict cancer development in patients with cirrhosis and detect early recurrence after resection
Why are gastrointestinal cancer patients getting younger?
Research is moving forward to adapt clinical practice to a new wave of early-onset cases of cancer in the digestive tract
Adjuvant immunotherapy reduces relapse risk in resected or ablated hepatocellular cancer
Data from the IMbrave050 study show benefits of atezolizumab plus bevacizumab in terms of disease recurrence, but long-term data are needed